bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 [Yahoo! Finance]
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: Yahoo! Finance
Number of physician offices signed increased 75% over Q2 2024 Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary SAN ANTONIO, November 14, 2024 BUSINESS WIRE bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024. Key Highlights Generated quarterly revenue of $2.4 million in the third quarter of 2024. More than 1,300% growth rate for CyPath ® Lung orders in first nine months of 2024 over full-year 2023. Number of physician offices signed increased by 75% compared to the second quarter of 2024, setting the stage for acceleration of CyPath ® Lung sales in the quarters ahead. In October 2024, CyPath ® Lung was added to the U.S. Federal Supply Schedule (FSS), a procurement system that provides the Veterans Healt
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024Business Wire
- bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product DevelopmentBusiness Wire
- U.S. Testing Laboratories, Safety and Compliance Services Industry Report 2024: Market Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]Yahoo! Finance
- bioAffinity Technologies Announces Award of Japanese Patent for CyPath® LungBusiness Wire
- WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private PlacementPR Newswire
BIAF
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 11/13/24 - Form PRE
- BIAF's page on the SEC website